Significant Agreements (Details) - USD ($) |
1 Months Ended | 9 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|
Jul. 13, 2021 |
Feb. 08, 2021 |
Jul. 19, 2021 |
Sep. 30, 2018 |
Oct. 31, 2017 |
Sep. 30, 2021 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|
| Significant Agreements (Details) [Line Items] | |||||||||
| Company agreement description | According to the terms of the agreement Unicycive will pay the vendor $2 million in the first calendar year when the net revenue reaches $10 million from sales of Renazorb following its approval by the FDA and commercial supply of the product by the vendor (First Payment). Thereafter, we will pay $2 million per year for four consecutive years, after the first year’s payment, for the total payments of $10 million, provided all commercial supplies are continued to be manufactured and supplied by the vendor. | ||||||||
| License agreement | No payments were made upon execution of the agreement but rather payments for $50,000 will be due commencing with the initiation by the Company of a second clinical trial and $50,000 on completion of such trial. At the time the FDA accepts a NDA application submitted by the Company for the product, the Company will pay Sphaera $1.65 million. Upon commercialization and sale of the drug product, royalty payments will also be payable quarterly to Sphaera equal to 2% of net sales on the preceding quarter. | ||||||||
| Company issued shares (in Shares) | 105,897 | 149,762 | |||||||
| Common stock valued | $ 142,000 | ||||||||
| Public market capitalization | $ 50,000,000 | ||||||||
| Anti-dilution shares of common stock (in Shares) | 438,374 | ||||||||
| Research and development expenses | $ 2,200,000 | ||||||||
| Purchase agreement, description | The Company is also required to pay Spectrum 40% of all of the Company’s sublicense income for any sublicense granted to certain sublicensees during the first 12 months after the Closing Date (as that term is defined in the Renazorb Purchase Agreement) and 20% of all other sublicense income. The Company’s payment obligations to Spectrum will expire on the twentieth (20th) anniversary of the Closing Date of the Renazorb Purchase Agreement. | ||||||||
| Development agreement description | The budget for the initial SOW is approximately 24,000,000 Japanese Yen, and an upfront payment of approximately $87,000, was paid to Ascent upon the execution of the Renazorb Development Agreement. Deliverables for the initial SOW were completed by December 31, 2021. | ||||||||
| Spectrum Pharmaceuticals, Inc. [Member] | |||||||||
| Significant Agreements (Details) [Line Items] | |||||||||
| Company issued shares (in Shares) | 313,663 | ||||||||
| Common stock valued | $ 4,000 | ||||||||
| Interest on ownership | 4.00% | ||||||||
| Market capitalization | $ 50,000,000 | ||||||||
| Cash recognized | $ 104,000 | $ 145,000 | |||||||
| Syneos Health LLC [Member] | |||||||||
| Significant Agreements (Details) [Line Items] | |||||||||
| Significant agreements description | the Company entered into an agreement with Syneos Health LLC (“Syneos”) pursuant to which Syneos will provide preclinical research and analysis services related to the development of UNI-494. The budget for the initial study, which will also include clinical pharmacology, translational sciences, and bioanalytical services, is approximately $1.9 million, and related payments totaling approximately $379,000 have been paid to Syneos during the year ended December 31, 2021. | ||||||||